Free Trial

DURECT Q3 2023 Earnings Report

DURECT logo
$0.78 -0.03 (-3.16%)
As of 02/21/2025 03:42 PM Eastern

DURECT EPS Results

Actual EPS
-$0.40
Consensus EPS
-$0.41
Beat/Miss
Beat by +$0.01
One Year Ago EPS
N/A

DURECT Revenue Results

Actual Revenue
$1.74 million
Expected Revenue
$2.52 million
Beat/Miss
Missed by -$780.00 thousand
YoY Revenue Growth
N/A

DURECT Announcement Details

Quarter
Q3 2023
Time
N/A

Conference Call Resources

DURECT Earnings Headlines

Durect Corporation Announces Board Member’s Retirement
StockNews.com Begins Coverage on DURECT (NASDAQ:DRRX)
Nvidia’s CEO: “This Will Be a Multitrillion-Dollar Industry."
If you missed out on the big boom in Nvidia… Listen up, because according to Nvidia's own CEO… Elon Musk’s new technology could help launch an entirely new multitrillion-dollar industry.
H.C. Wainwright views Durect as significant ‘going concern’ risk
See More DURECT Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like DURECT? Sign up for Earnings360's daily newsletter to receive timely earnings updates on DURECT and other key companies, straight to your email.

About DURECT

DURECT (NASDAQ:DRRX), a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. It also offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine over three days in adults; and Methydur to treat attention deficit hyperactivity disorder. It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in other countries. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; and Innocoll Pharmaceuticals Limited. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California.

View DURECT Profile

More Earnings Resources from MarketBeat